Inqovi
Active Ingredient(s): Decitabine + CedazuridineFDA Approved: * July 7, 2020
Pharm Company: * ASTEX PHARMACEUTICALS INC
Category: Cancer
Decitabine/cedazuridine, sold under the brand name Inqovi, is a fixed-dose combination medication for the treatment of adults with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).[5][6][7] It is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor.[5][6][7][8][9] The most common sid... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.Dosage List
